Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MULTI-EXA: multiplex PCR, procalcitonin and sputum appearance to reduce antibiotic duration in severe COPD exacerbation
2024-511896-13-00Phase 4Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2024
- Modality
- Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of amoxicillin + clavulanate, cefepime, cefotaxime, spiramycin and piperacillin + tazobactam in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Number of days alive without antibiotics on day 28. Started Oct 2024; status: completed.
02
Drugs
amoxicillin + clavulanatecefepimecefotaximespiramycinpiperacillin + tazobactam
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2024-511896-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511896-13-00.